Shanghai Pharmaceuticals Renews Framework Agreement with Yunnan Baiyao

Shanghai Pharmaceuticals Holding Co (HK:2607) has released an update.

Shanghai Pharmaceuticals Holding Co. has renewed its Sales and Procurement Framework Agreement with Yunnan Baiyao for 2025, securing another year of collaboration. The partnership involves the exchange of medicines, medical devices, and health products, leveraging each company’s strength as a producer or main distributor. This agreement, a continuing connected transaction, will not require independent shareholders’ approval under Hong Kong’s listing rules.

For further insights into HK:2607 stock, check out TipRanks’ Stock Analysis page.